Barinthus Biotherapeutics plc - American Depositary Shares BRNS 深 滬
等待開盤 08-15 09:30:00 美东时间
1.2759
+0.016
+1.26%
華盛通- 最 高1.3873
- 今 開1.24
- 成交量 1.21万股
- 最 低 1.1801
- 昨 收 1.26
- 總市值 5146.90万
- 52周最高 2.92
- 市盈率 靜 --
- 換手率 0.03%
- 52周最低 0.64
- 委 比 -41.33%
- 總股本 4033.94万
- 歷史最高 17.99
- 量 比 0.25
- 振 幅 16.44%
- 歷史最低 0.64
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Equillium (NASDAQ:EQ) shares moved upwards by 98.9% to $0.98 during Mo...
08-12 01:06
Barinthus Biotherapeutics GAAP EPS of -$0.52
Barinthus Biotherapeutics press release (NASDAQ:BRNS): Q2 GAAP EPS of -$0.52. As of June 30, 2025, cash, cash equivalents and restricted cash was $87.8 million, compared to $100.6 million as of March ...
08-07 23:13
Barinthus Biotherapeutics Q2 EPS $(0.52) Misses $(0.33) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.33) by 57.58 percent. This is a 20.93 percent decrease over losses of $(0.43) per
08-07 20:12
Barinthus Biotherapeutics Q1 EPS $(0.49) Misses $(0.36) Estimate
Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.36) by 36.11 percent. This is a 22.5 percent decrease over losses of $(0.40) per
05-07 21:20
Barinthus Biotherapeutics Restructures Leadership with New CFO
Barinthus Biotherapeutics ( ($BRNS) ) has issued an update. Barinthus Biotherap...
05-07 20:28
美股大行评级 | 高盛：上调Adaptive Biotechnologies评级至"买入"，目标价从8美元升至9美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1110125309827231744.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Oppenheimer：维持Amprius Technologies(AMPX)"跑赢大市"评级，目标价从14美元升至15美元</p> <p>• 韦德布什：维持Monte Rosa Therapeutics(GLUE)"跑
03-24 07:31
H.C. Wainwright Sticks to Its Buy Rating for Barinthus Biotherapeutics (BRNS)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Barinthus Biotherape...
03-21 18:46
美股大行评级 | 潜在涨幅224%！Ultragenyx制药获Piper Sandler上调目标价至140美元，维持“超配”评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1085846677098434561.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Piper Sandler：维持Ultragenyx制药(RARE)"超配"评级，目标价从135美元升至140美元</p> <p>• Leerink Partners：维持ARS Pharmaceuticals(SPRY)
01-14 09:51
Barinthus Biotherapeutics Appoints New Chief Scientific Officer
An announcement from Barinthus Biotherapeutics ( ($BRNS) ) is now available. Ba...
2024-11-26 05:35
Barinthus Biotherapeutics Reports Promising IM-PROVE II Trial Results
The latest update is out from Barinthus Biotherapeutics ( ($BRNS) ). Barinthus ...
2024-11-16 00:30
